Topical Beremagene Geperpavec
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Dystrophic Epidermolysis Bullosa
Conditions
Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
Trial Timeline
Aug 17, 2020 → Jan 14, 2022
NCT ID
NCT04491604About Topical Beremagene Geperpavec
Topical Beremagene Geperpavec is a phase 3 stage product being developed by Krystal Biotech for Dystrophic Epidermolysis Bullosa. The current trial status is completed. This product is registered under clinical trial identifier NCT04491604. Target conditions include Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa.
What happened to similar drugs?
0 of 2 similar drugs in Dystrophic Epidermolysis Bullosa were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04491604 | Phase 3 | Completed |
Competing Products
4 competing products in Dystrophic Epidermolysis Bullosa
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KB803 + Placebo | Krystal Biotech | Phase 3 | 44 |
| Topical beremagene geperpavec + Placebo gel | Krystal Biotech | Phase 1/2 | 29 |
| Open Label Topical Beremagene Geperpavec (B-VEC) | Krystal Biotech | Phase 3 | 37 |
| LZRSE-Col7A1 Engineered Autologous Epidermal Sheets | Abeona Therapeutics | Phase 1/2 | 22 |